These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34254905)

  • 1. Research Progress of DCLK1 Inhibitors as Cancer Therapeutics.
    Cheng L; Huang S; Chen L; Dong X; Zhang L; Wu C; Ye K; Shao F; Zhu Z; Thorne RF
    Curr Med Chem; 2022; 29(13):2261-2273. PubMed ID: 34254905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic Landscape and Therapeutic Implication of Gene Isoforms of Doublecortin-Like Kinase 1 for Cancer Stem Cells.
    Moore LL; Houchen CW
    Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.
    Chandrakesan P; Yao J; Qu D; May R; Weygant N; Ge Y; Ali N; Sureban SM; Gude M; Vega K; Bannerman-Menson E; Xia L; Bronze M; An G; Houchen CW
    Mol Cancer; 2017 Feb; 16(1):30. PubMed ID: 28148261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
    Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
    Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Doublecortin-Like Kinase 1 (DCLK1) Regulates B Cell-Specific Moloney Murine Leukemia Virus Insertion Site 1 (Bmi-1) and is Associated with Metastasis and Prognosis in Pancreatic Cancer.
    Li J; Wang Y; Ge J; Li W; Yin L; Zhao Z; Liu S; Qin H; Yang J; Wang L; Ni B; Liu Y; Wang H
    Cell Physiol Biochem; 2018; 51(1):262-277. PubMed ID: 30453285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doublecortin-like kinase 1 promotes hepatocyte clonogenicity and oncogenic programming via non-canonical β-catenin-dependent mechanism.
    Ali N; Nguyen CB; Chandrakesan P; Wolf RF; Qu D; May R; Goretsky T; Fazili J; Barrett TA; Li M; Huycke MM; Bronze MS; Houchen CW
    Sci Rep; 2020 Jun; 10(1):10578. PubMed ID: 32601309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule kinase inhibitor LRRK2-IN-1 demonstrates potent activity against colorectal and pancreatic cancer through inhibition of doublecortin-like kinase 1.
    Weygant N; Qu D; Berry WL; May R; Chandrakesan P; Owen DB; Sureban SM; Ali N; Janknecht R; Houchen CW
    Mol Cancer; 2014 May; 13():103. PubMed ID: 24885928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting colon cancer stem cells using novel doublecortin like kinase 1 antibody functionalized folic acid conjugated hesperetin encapsulated chitosan nanoparticles.
    Lazer LM; Kesavan Y; Gor R; Ramachandran I; Pathak S; Narayan S; Anbalagan M; Ramalingam S
    Colloids Surf B Biointerfaces; 2022 Sep; 217():112612. PubMed ID: 35738074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
    Liu Y; Ferguson FM; Li L; Kuljanin M; Mills CE; Subramanian K; Harshbarger W; Gondi S; Wang J; Sorger PK; Mancias JD; Gray NS; Westover KD
    Cell Chem Biol; 2020 Oct; 27(10):1229-1240.e4. PubMed ID: 32755567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of doublecortin-like kinase 1 inhibitors and their bioactivity evaluation.
    Pan P; Ji D; Li Z; Meng X
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2287990. PubMed ID: 38062554
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.
    Kim JH; Park SY; Jeon SE; Choi JH; Lee CJ; Jang TY; Yun HJ; Lee Y; Kim P; Cho SH; Lee JS; Nam JS
    Theranostics; 2022; 12(12):5258-5271. PubMed ID: 35910805
    [No Abstract]   [Full Text] [Related]  

  • 12. Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.
    Carli ALE; Afshar-Sterle S; Rai A; Fang H; O'Keefe R; Tse J; Ferguson FM; Gray NS; Ernst M; Greening DW; Buchert M
    Proteomics; 2021 Jul; 21(13-14):e2000098. PubMed ID: 33991177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
    Kang XL; He LR; Chen YL; Wang SB
    World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Doublecortin-like kinase 1 is elevated serologically in pancreatic ductal adenocarcinoma and widely expressed on circulating tumor cells.
    Qu D; Johnson J; Chandrakesan P; Weygant N; May R; Aiello N; Rhim A; Zhao L; Zheng W; Lightfoot S; Pant S; Irvan J; Postier R; Hocker J; Hanas JS; Ali N; Sureban SM; An G; Schlosser MJ; Stanger B; Houchen CW
    PLoS One; 2015; 10(2):e0118933. PubMed ID: 25723399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.
    Ito H; Tanaka S; Akiyama Y; Shimada S; Adikrisna R; Matsumura S; Aihara A; Mitsunori Y; Ban D; Ochiai T; Kudo A; Arii S; Yamaoka S; Tanabe M
    PLoS One; 2016; 11(1):e0146564. PubMed ID: 26764906
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.
    Ikezono Y; Koga H; Akiba J; Abe M; Yoshida T; Wada F; Nakamura T; Iwamoto H; Masuda A; Sakaue T; Yano H; Tsuruta O; Torimura T
    Mol Cancer Res; 2017 Jun; 15(6):744-752. PubMed ID: 28179411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.
    Nevi L; Di Matteo S; Carpino G; Zizzari IG; Samira S; Ambrosino V; Costantini D; Overi D; Giancotti A; Monti M; Bosco D; De Peppo V; Oddi A; De Rose AM; Melandro F; Bragazzi MC; Faccioli J; Massironi S; Grazi GL; Panici PB; Berloco PB; Giuliante F; Cardinale V; Invernizzi P; Caretti G; Gaudio E; Alvaro D
    Hepatology; 2021 Jan; 73(1):144-159. PubMed ID: 32978808
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spatial and temporal diversity of DCLK1 isoforms in developing mouse brain.
    Bergoglio E; Suzuki IK; Togashi K; Tsuji M; Takeuchi S; Koizumi H; Emoto K
    Neurosci Res; 2021 Sep; 170():154-165. PubMed ID: 33485913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of DCLK1 in oncogenic signaling (Review).
    Lu Q; Feng H; Chen H; Weygant N; Du J; Yan Z; Cao Z
    Int J Oncol; 2022 Nov; 61(5):. PubMed ID: 36148883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.
    Sakaguchi M; Hisamori S; Oshima N; Sato F; Shimono Y; Sakai Y
    Mol Cancer Res; 2016 Apr; 14(4):354-62. PubMed ID: 26747706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.